Advertisement
Xenetic Biosciences, Inc. (XBIO)
NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 3.9200 |
| Open | 4.0200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 3.9000 - 4.2004 |
| 52 Week Range | 2.7800 - 5.2000 |
| Volume | |
| Avg. Volume | 19,671 |
| Market Cap | 6.33M |
| Beta (5Y Monthly) | 2.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6600 |
| Earnings Date | Nov 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting Watch the "What This Means" ...
- ACCESSWIRE
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the presentation of preclinical data investigating ...
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.